Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
1.7 USD -10.53% Intraday chart for Adial Pharmaceuticals, Inc. -24.11% -8.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder MT
Top Premarket Decliners MT
Top Midday Gainers MT
Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder CI
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Adial Pharmaceuticals, Inc. announced that it has received $0.2875 million in funding CI
Adial Pharmaceuticals, Inc. announced that it expects to receive $0.2875 million in funding CI
Top Premarket Decliners MT
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell MT
US Futures Remain Flat as Investors Await Raft of Economic Data MT
Top Midday Gainers MT
Adial Pharmaceuticals Secures US Patent Allowance for AD04, Genetic Diagnostic Combination MT
Adial Pharmaceuticals Receives New Patent Notice of Allowance from the United States Patent and Trademark Office CI
Adial Pharmaceuticals Appoints Tony Goodmans as Chief Operating Officer MT
Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer CI
Top Premarket Gainers MT
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Adial Pharmaceuticals, Inc. announced that it has received $4.000001 million in funding CI
Adial Pharmaceuticals, Inc. announced that it expects to receive $4.000001 million in funding CI
Adial Pharmaceuticals Awarded Patent Combining Use of Genetic Diagnostic With AD04 to Treat Alcohol, Drug Dependence MT
Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence CI
Adial Pharmaceuticals, Inc. Announces Board Changes CI
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Adial Pharma to Conduct Two More AD04 Phase 3 Trials After Regulatory Feedback DJ
Adial Pharmaceuticals, Inc.(NasdaqCM:ADIL) dropped from Russell 3000E Growth Index CI
Chart Adial Pharmaceuticals, Inc.
More charts
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company’s drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (AUD). AD04 is used for the treatment of AUD in subjects with certain target genotypes, which were identified using its companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, a therapeutic agent for the treatment of AUD. The Company’s AD04 also has the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.7 USD
Average target price
7.5 USD
Spread / Average Target
+341.18%
Consensus